Abstract
Mycobacterium tuberculosis has caused tuberculosis (TB) in humans for at least 3 millennia, but the disease has evaded eradication efforts by all human civilisations despite promising technological advancements. The World Health Organization (WHO) has set a target of ending the TB epidemic by 2035. Going by the current rate of progress, it is estimated that it will take another 160 years to realise the WHO End TB Strategy’s target. Accelerating the eradication of TB will require effective tools for diagnosis, vaccines and medicines to treat the disease, and efficient implementation thereof. This presents a great opportunity for innovators in East Africa and the world over to chip in and develop the best technologies to end TB. With funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), partnerships between the UK-based University of St Andrews and research institutions in East and Southern Africa have led to the development of the first ever test – the molecular bacterial load assay (MBLA) – that measures the number of TB bacteria in a patient and reveals if this number is declining as a patient progresses on treatment. Initial assay results are available within 4 hours. Real-time knowledge of patient mycobacterial burden and the effectiveness of prescribed medications are crucial for timely clinical decisions on patient management.
Highlights
Mycobacterium tuberculosis has caused tuberculosis (TB) in humans for at least 3 millennia, but the disease has evaded eradication efforts by all human civilisations despite promising technological advancements
According to the World Health Organization (WHO), 30 countries are categorised as high–TB-burden countries (HBCs) and account for 87% of the global TB burden
The molecular bacterial load assay (MBLA) test is specific to TB, and it has a faster turnaround time (TAT) than culture, taking only 24 hours for results to be received at the clinic
Summary
Mycobacterium tuberculosis has caused tuberculosis (TB) in humans for at least 3 millennia, but the disease has evaded eradication efforts by all human civilisations despite promising technological advancements. The WHO has set a target of ending the TB epidemic by 2035.4 Going by the current rate of progress, it is estimated that it will take another 160 years to realise the WHO End TB Strategy’s target.[5] Accelerating the eradication of TB will require effective tools for diagnosis, vaccine and medicines to treat the disease, and efficient implementation thereof This presents a great opportunity for innovators in ES and the world over to chip in and develop the best technologies to end TB. Rapid Test for Measuring Individual TB Bacterial Load www.eahealth.org edge of patient mycobacterial burden and the effectiveness of prescribed medications are crucial for timely clinical decisions on patient management This is a great improvement over the tools currently used for TB diagnosis and treatment monitoring. MBLA, is a technological solution to these challenges drawing on recent advances in molecular biology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
